Prophylactic administration of IFNs at the early stage prior to pneumonia progression may antagonize the viral suppression on IFN production and elicit an autonomous antiviral state in affected cells to block viral infection and COVID-19 pathogenesis. The gene discussed is IFNA1; the disease is COVID-19.